159
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

ORCID Icon, , ORCID Icon, , & ORCID Icon
Pages 2187-2199 | Published online: 04 Nov 2020

Figures & data

Table 1 Characteristics of Oral and Injectable DMA Users with MS and the Standard Differences of Covariates Between Both Groups Before and After IPTW Weighting: IBM MarketScan 2010–2012

Figure 1 Flowchart For Study Cohort Derivation: IBM MarketScan 2010–2012.

Figure 1 Flowchart For Study Cohort Derivation: IBM MarketScan 2010–2012.

Figure 2 Adherence Trajectories of Patients with MS who received Oral Fingolimod or Injectable DMAs. Rapid discontinuers: Patients who discontinued DMAs early within 3–4 months after the initiation. Complete adherers: Patients who were almost completely adherent to DMA throughout the follow-up period. Slow decliners: Patients whose adherence gradually declined during the follow-up period.

Abbreviations: MS, multiple sclerosis; DMA, disease modifying agent.
Figure 2 Adherence Trajectories of Patients with MS who received Oral Fingolimod or Injectable DMAs. Rapid discontinuers: Patients who discontinued DMAs early within 3–4 months after the initiation. Complete adherers: Patients who were almost completely adherent to DMA throughout the follow-up period. Slow decliners: Patients whose adherence gradually declined during the follow-up period.

Table 2 Adherence Trajectories Between Oral Fingolimod and Injectable DMA Users in Patients with MS

Table 3 Findings of IPTW Weighted Multinomial Logistic Regression